GHK-Cu, BPC-157, TB-500, and KPV in a single formulation. What each component does, how they work together, and what the research actually shows.
KLOW Blend combines four well-researched peptides — GHK-Cu, BPC-157, TB-500, and KPV — into a single lyophilized formulation. The idea is straightforward: each compound targets a different aspect of healing and inflammation, and combining them in research eliminates the complexity of managing multiple vials, reconstitutions, and injection schedules.
The name is an acronym of the four components: KPV, Lyophilized base, One-vial delivery, Wound repair stack — or more simply, the initials of each peptide's key letter. The blend is offered by S1 Research as an 80mg vial covering all four compounds at functional research concentrations.
All four components have been studied individually in preclinical (animal and in vitro) models. The KLOW Blend as a combined formulation has not been independently studied in peer-reviewed literature — the research rationale is based on the individual compound evidence and their complementary mechanisms.
Understanding the blend starts with understanding what each piece brings to the table.
| Peptide | Primary Target | Mechanism | Evidence Level |
|---|---|---|---|
| GHK-Cu | Skin, connective tissue | Fibroblast activation, copper signaling | Strong preclinical |
| BPC-157 | Tendons, ligaments, gut | VEGF upregulation, NO signaling | Extensive preclinical (100+ studies) |
| TB-500 | Systemic inflammation | Actin sequestration, cell migration | Strong preclinical |
| KPV | Gut, systemic inflammation | NF-kB inhibition, cytokine reduction | Good preclinical |
The case for combining these four compounds is that they operate on different but complementary healing pathways — covering local tissue repair, systemic inflammation, collagen remodeling, and immune-mediated inflammation at the same time.
BPC-157 handles local repair. It works where you inject it, upregulating growth factors that drive blood vessel formation and tissue rebuilding near the injury site. This is your targeted, site-specific compound.
TB-500 covers what BPC-157 misses. It works systemically, circulating throughout the body and reducing inflammatory signaling in tissues that aren't close to the injection. For diffuse injuries or full-body recovery protocols, this is the key piece BPC-157 alone can't provide.
GHK-Cu adds a remodeling layer. Once initial healing is underway, collagen and elastin quality matter. GHK-Cu has been studied specifically for improving the structural quality of repaired tissue — not just sealing the wound but improving what grows back.
KPV addresses immune-mediated inflammation. Some inflammatory processes are driven by the immune system rather than direct tissue damage. KPV's NF-kB inhibition targets this pathway, which BPC-157 and TB-500 don't directly address. For research involving chronic inflammation or gut pathology, KPV adds a mechanism the others don't cover.
Managing four separate vials, four reconstitutions, and four injection schedules adds significant complexity to a research protocol. A pre-formulated blend eliminates that overhead — though it also removes the ability to adjust individual component doses independently.
Because KLOW is a blend rather than a standalone compound, dosing follows vendor-specified concentrations rather than a single compound's established protocol. The 80mg vial from S1 Research contains all four peptides at their standard research ratios.
| Parameter | Value |
|---|---|
| Vial size | 80mg (total blend) |
| Route | SubQ injection |
| Frequency | Daily or every other day |
| Cycle length | 6–12 weeks |
| Reconstitution | Bacteriostatic water (1–2mL) |
| Storage | Refrigerate after reconstitution; use within 28 days |
Individual component concentrations within the blend are determined by the vendor formulation. Researchers who need precise dosing control over each compound individually should consider sourcing them separately rather than as a blend.
KLOW and Glow Blend are often compared since both are multi-peptide recovery stacks available from overlapping vendors. The key difference is the fourth component.
| Component | KLOW Blend | Glow Blend |
|---|---|---|
| BPC-157 | ✓ | ✓ |
| TB-500 | ✓ | ✓ |
| GHK-Cu | ✓ | ✓ |
| KPV | ✓ | ✗ |
| Total vial size | 80mg | 70mg |
| Primary focus | Comprehensive recovery + inflammation | Skin, collagen, recovery |
Glow Blend is the simpler three-compound stack — BPC-157, TB-500, and GHK-Cu — which makes it more focused on aesthetic and structural repair. KLOW adds KPV for gut and immune-mediated inflammation coverage, making it the more comprehensive option for research involving chronic inflammation or gut pathology alongside musculoskeletal healing.
If your research focus is purely tissue repair and skin regeneration, Glow Blend is sufficient. If it involves systemic inflammation, gut tissue, or you want the broadest coverage possible, KLOW is the more complete formulation.
Side-by-side vendor pricing, COA status, and discount codes — all on the main peptide card.
View KLOW Blend Prices → Wolverine Stack Guide